At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
Selpercatinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, 3-Period, Fixed Sequence Study to Evaluate the Effect of an H2 Antagonist and a Proton Pump Inhibitor on the Single Dose Pharmacokinetics of LOXO-292 in Healthy Adult Subjects
In Brief
A Phase 1 clinical trial evaluating Selpercatinib, Ranitidine, and 1 other intervention for Healthy. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The main purpose of this study is to learn about how H2 antagonist (ranitidine) and proton pump inhibitor (PPI) (omeprazole) affect Selpercatinib in healthy participants. Information about safety and tolerability will be collected. The study will last up to about 9 weeks, inclusive of screening period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsLoxo Oncology, Inc.
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
Enrollment StartJul 2019
Primary CompletionSep 2019
First PostedApr 2022
TodayJul 2026
First PostedApr 21, 2022
Enrollment StartJul 8, 2019
Primary CompletionSep 3, 2019
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 4.2 years ago
Interventions
Selpercatinibdrug
Administered orally.
Ranitidinedrug
Administered orally.
Omeprazoledrug
Administered orally.